Can we patent products found in nature? It's complicated. An update on Australia's Myriad decision...

by JD Supra Perspectives

A recent decision by the High Court of Australia found that genes are not patentable inventions. In the case, Myriad Genetics owned a patent covering mutations they had discovered in the BRCA1 gene. Myriad discovered that patients with those gene mutations had a higher incidence of developing breast cancer. The patent had claims that listed the specific nucleic acid sequence of the mutant BRCA1 genes. Myriad developed diagnostic tests that used the mutant nucleic acid sequences to predict the likelihood of a patient developing breast cancer.

This case started when a cancer survivor in Australia, Yvonne D’Arcy sued to challenge the validity of the claims. She argued that the patent claims were actually directed to “information embodied in the arrangement of nucleotides” instead of gene molecules themselves. She then argued that this gene information, which covered the sequence of the mutant genes, was not a product of human action.

In order for an invention to be patentable in Australia, it needs to be the product of human action. Ms. D’Arcy lost in the first Federal Court, and also at an appeal to the full Federal Court. Both of these courts found that genes which were isolated or purified from a person are a result of human action. The courts reasoned that these isolated genes were not the same as what exists in the human body, and were discovered by the human action of isolating them.

...while isolating the DNA encoding the mutant gene may have involved human action, it was the information stored in the nucleic acids making up the mutant gene that was really being patented.

Ms. D’Arcy appealed to the High Court, which is similar to the Supreme Court in the United States. The High Court took the case, and on October 7, 2015 ruled unanimously that the claimed invention "did not fall within the concept of a manner of manufacture.” The High Court reasoned that while isolating the DNA encoding the mutant gene may have involved human action, it was the information stored in the nucleic acids making up the mutant gene that was really being patented. And, according to the High Court, that information was not the product of human action. It was the product of the nature of genes. The High Court therefore found for Ms. D’Arcy and invalidated the patent claims on the BRCA1 genes.

A very similar result has already occurred in the United States. On June 13, 2013, the U.S. Supreme Court found that the U.S. versions of Myriad’s patents covering BRCA1 mutant genes were unpatentable. The Supreme Court found that isolated DNA, such as claimed in Myriad’s BRCA1 gene patent, was not patentable because the claimed subject matter was a product of nature. Although the U.S. Supreme Court noted that isolated DNA encoded the same information as the DNA in situ, the Court did not find that the gene claims were merely “information” as in Australia. Instead they found that the claimed genes were unpatentable products of nature.

...they found that the claimed genes were unpatentable products of nature.

In some ways the Australian case seems more narrow, since the rationale used by the High Court was that the “information” content of the patented gene was actually the invention, and not the isolated gene molecule itself. According to the Australian High Court, the information was not a product of human interaction. If that is the rationale, then the Australian decision may not easily be extended to other natural chemical compounds which don’t carry information.

This contrasts with the U.S. Supreme Court rationale which found that the mere act of isolating or purifying the BRCA1 genes was not enough to differentiate it from the genes as they occurred in nature. This led to the broader holding in the U.S. that products merely isolated from nature, without significantly more inventive input, are not patentable inventions.

In the U.S., the Myriad decision has already had far-reaching effects on the ability of companies to patent naturally-derived biological discoveries. Any product derived from nature, no matter how tangentially, is now subject to strong scrutiny and rejection by the U.S. Patent Office (USPTO). Well-known, valuable medications, such as antibiotics discovered in living organisms are argued to be unpatentable by the USPTO because the original antibiotic compounds were found in nature. The business model of looking to natural resources for drug candidates has been greatly eroded because pharmaceutical companies know that any compound discovered this way cannot be patented.

Any product derived from nature, no matter how tangentially, is now subject to strong scrutiny and rejection by the U.S. Patent Office...

It seems very likely that courts in other countries are watching these results. It’s also likely that patients and patient’s rights groups will continue to bring challenges, like those brought in the U.S. and Australian cases, to gene-based patents as a way to reduce the cost of diagnostic tests, which they argue are overpriced due to exclusion of lower-priced competition by the patent protection. On the other hand, diagnostic companies, such as Myriad, will continue to argue that they will have little incentive to spend the millions of dollars required to develop and validate these tests if competitors can copy them as soon as they are launched.

It remains to be seen if this new decision in Australia will be extended as it was in the U.S. to prevent virtually any product found in nature from being patented. We will have to watch and see how future cases in Australia interpret this new case, and also how the rest of the world begins to analyze patents covering gene-based inventions. Other than the U.S., and now Australia, most other countries still allow patents on genes. So we can expect to see additional challenges as the rest of the world grapples with the issues presented in these cases.


[Mike Fuller is the Co-Managing Partner of intellectual property law firm Knobbe Martens' San Diego office and chair of the firm’s biotech practice group. Follow his additional analysis and commentary here.]

Written by:

JD Supra Perspectives

JD Supra Perspectives on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.